並列タイトル等肝細胞癌の細胞周期とマイクロRNAを介したレンバチニブの治療効果の検討
一般注記Lenvatinib is a tyrosine kinase receptor inhibitor used to treat unresectable hepatocellular carcinoma (HCC). In this study, we investigated the antitumor effects of Lenvatinib treatment on HCC cell lines. Proliferation was examined in four HCC cell lines (HuH‑7, Hep3B, Li‑7, and PLC/PRF/5) using Cell Counting Kit‑8 assays. Xenograft mouse models were used to assess the effects of Lenvatinib in vivo. Cell cycle, western blotting, and microRNA (miRNA) expression analyses were performed to identify the antitumor inhibitory potential of Lenvatinib on HCC cells. Lenvatinib treatment suppressed proliferation of HuH‑7 and Hep3B, but not Li‑7 and PLC/PRF/5 cells and induced G0/G1 cell cycle arrest and cyclin D1 downregulation in Lenvatinib‑sensitive cells. Lenvatinib treatment also reduced tumor growth in HuH‑7 xenograft mouse models. miRNA microarrays revealed that Lenvatinib treatment altered the expression of miRNAs in HuH7 cells and exosomes. Our results demonstrated the therapeutic potential of Lenvatinib and provide molecular mechanistic insights into its antitumor effects for treating HCC.
コレクション（個別）国立国会図書館デジタルコレクション > デジタル化資料 > 博士論文
受理日（W3CDTF）2023-03-07T16:07:41+09:00
連携機関・データベース国立国会図書館 : 国立国会図書館デジタルコレクション